Large Pharmaceutical Companies Investing More In Start-Ups To Conduct Early Stage Research

CNBC: Big Pharma’s billion-dollar scramble to invest in start-ups to fuel innovation
“…Despite growing recognition of [the threat of antimicrobial resistance], there is an early stage funding gap for new treatments. … In response, industry giants like Novo Holdings — which has big stakes in Danish drugmaker Novo Nordisk — Merck, Johnson & Johnson, Sanofi, and others are looking to become more entrepreneurial. Increasingly, these big players are setting up venture capital funds and investing in start-ups and licensing technology to fuel their own drug pipelines. Many are also outsourcing R&D, while reducing product development efforts internally…” (Ioannou, 3/28).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.